Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016 (2016), Article ID 9895721, 7 pages
http://dx.doi.org/10.1155/2016/9895721
Research Article

Expressions of Matrix Metalloproteinases 2, 7, and 9 in Carcinogenesis of Pancreatic Ductal Adenocarcinoma

1Department of Pathomorphology, Comprehensive Cancer Center, 15-027 Białystok, Poland
2Department of General Pathomorphology, Medical University of Białystok, 15-269 Białystok, Poland
3Department of Reproduction and Gynecological Endocrinology, Medical University of Białystok, 15-276 Białystok, Poland
4Department of Rehabilitation, Medical University of Białystok, 15-276 Białystok, Poland
52nd Department of General and Gastroenterological Surgery, Medical University of Białystok, 15-276 Białystok, Poland

Received 22 March 2016; Revised 13 May 2016; Accepted 31 May 2016

Academic Editor: Massimiliano Castellazzi

Copyright © 2016 Katarzyna Jakubowska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Li, D. G. Heidt, P. Dalerba et al., “Identification of pancreatic cancer stem cells,” Cancer Research, vol. 67, no. 3, pp. 1030–1037, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. A. B. Lowenfels and P. Maisonneuve, “Epidemiology and risk factors for pancreatic cancer,” Best Practice and Research: Clinical Gastroenterology, vol. 20, no. 2, pp. 197–209, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. R. R. Baruch, H. Melinscak, J. Lo, Y. Liu, O. Yeung, and R. A. R. Hurta, “Altered matrix metalloproteinase expression associated with oncogene-mediated cellular transformation and metastasis formation,” Cell Biology International, vol. 25, no. 5, pp. 411–420, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. L. A. Shuman Moss, S. Jensen-Taubman, and W. G. Stetler-Stevenson, “Matrix metalloproteinases: changing roles in tumor progression and metastasis,” American Society for Investigative Pathology, vol. 181, no. 6, pp. 1895–1899, 2012. View at Publisher · View at Google Scholar
  5. N. E. Sounni, K. Dehne, L. L. C. L. van Kempen et al., “Stromal regulation of vessel stability by MMP9 and TGFβ,” Disease Models & Mechanisms, vol. 3, no. 5-6, pp. 317–332, 2010. View at Google Scholar
  6. A. Lekstan, P. Lampe, J. Lewin-Kowalik et al., “Concentrations and activities of metalloproteinases 2 and 9 and their inhibitors (TIMPS) in chronic pancreatitis and pancreatic adenocarcinoma,” Journal of Physiology and Pharmacology, vol. 63, no. 6, pp. 589–599, 2012. View at Google Scholar · View at Scopus
  7. M. D. Sternlicht and Z. Werb, “How matrix metalloproteinases regulate cell behavior,” Annual Review of Cell and Developmental Biology, vol. 17, pp. 463–516, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Monteagudo, M. J. Merino, J. San-Juan, L. A. Liotta, and W. G. Stetler-Stevenson, “Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue,” American Journal of Pathology, vol. 136, no. 3, pp. 585–592, 1990. View at Google Scholar · View at Scopus
  9. M. Bond, R. P. Fabunmi, A. H. Baker, and A. C. Newby, “Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-κB,” FEBS Letters, vol. 435, no. 1, pp. 29–34, 1998. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Groblewska, B. Mroczko, M. Gryko et al., “Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients,” Tumor Biology, vol. 35, no. 4, pp. 3793–3802, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. J. C. Nickel, L. D. True, J. N. Krieger, R. E. Berger, A. H. Boag, and I. D. Young, “Consensus development of a histopathological classification system for chronic prostatic inflammation,” BJU International, vol. 87, no. 9, pp. 797–805, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. C. H. Richards, K. M. Flegg, C. S. D. Roxburgh et al., “The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer,” British Journal of Cancer, vol. 106, no. 12, pp. 2010–2015, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. G. J. Krejs, “Pancreatic cancer: epidemiology and risk factors,” Digestive Diseases, vol. 28, no. 2, pp. 355–358, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. S.-Z. Chen, H.-Q. Yao, S.-Z. Zhu, Q.-Y. Li, G.-H. Guo, and J. Yu, “Expression levels of matrix metalloproteinase-9 in human gastric carcinoma,” Oncology Letters, vol. 9, no. 2, pp. 915–919, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Pryczynicz, M. Gryko, K. Niewiarowska et al., “Immunohistochemical expression of MMP-7 protein and its serum level in colorectal cancer,” Folia Histochemica et Cytobiologica, vol. 51, no. 3, pp. 206–212, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Ochoa-Callejero, I. Toshkov, S. Menne, and A. Martínez, “Expression of matrix metalloproteinases and their inhibitors in the woodchuck model of hepatocellular carcinoma,” Journal of Medical Virology, vol. 85, no. 7, pp. 1127–1138, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Giannopoulos, K. Pavlakis, A. Parasi et al., “The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters,” Anticancer Research, vol. 28, no. 3, pp. 1875–1882, 2008. View at Google Scholar · View at Scopus
  18. T. M. Gress, F. Müller-Pillasch, M. M. Lerch, H. Friess, H. Büchler, and G. Adler, “Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer,” International Journal of Cancer, vol. 62, no. 4, pp. 407–413, 1995. View at Publisher · View at Google Scholar · View at Scopus
  19. H. D. Li, C. Huang, K. J. Huang et al., “STAT3 knockdown reduces pancreatic cancer cell invasiveness and matrix metalloproteinase-7 expression in nude mice,” PLoS ONE, vol. 6, no. 10, Article ID e25941, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. H. C. Crawford, C. R. Scoggins, M. K. Washington, L. M. Matrisian, and S. D. Leach, “Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas,” The Journal of Clinical Investigation, vol. 109, no. 11, pp. 1437–1444, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. Y.-J. Li, Z.-M. Wei, Y.-X.-Y. Meng, and X.-R. Ji, “Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis,” World Journal of Gastroenterology, vol. 11, no. 14, pp. 2117–2123, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. L. E. Jones, M. J. Humphreys, F. Campbell, J. P. Neoptolemos, and M. T. Boyd, “Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival,” Clinical Cancer Research, vol. 10, no. 8, pp. 2832–2845, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Yamamoto, F. Itoh, S. Iku et al., “Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression,” Journal of Clinical Oncology, vol. 19, no. 4, pp. 1118–1127, 2001. View at Google Scholar · View at Scopus
  24. X. Tan, H. Egami, S. Ishikawa et al., “Involvement of matrix metalloproteinase-7 in invasion-metastasis through induction of cell dissociation in pancreatic cancer,” International Journal of Oncology, vol. 26, no. 5, pp. 1283–1289, 2005. View at Google Scholar · View at Scopus
  25. D.-H. Zhou, A. Trauzold, C. Röder, G. Pan, C. Zheng, and H. Kalthoff, “The potential molecular mechanism of overexpression of uPA, IL-8, MMP-7 and MMP-9 induced by TRAIL in pancreatic cancer cell,” Hepatobiliary and Pancreatic Diseases International, vol. 7, no. 2, pp. 201–209, 2008. View at Google Scholar · View at Scopus
  26. S. R. Harvey, T. C. Hurd, G. Markus et al., “Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer,” Clinical Cancer Research, vol. 9, no. 13, pp. 4935–4943, 2003. View at Google Scholar · View at Scopus
  27. G. Bergers, R. Brekken, G. McMahon et al., “Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis,” Nature Cell Biology, vol. 2, no. 10, pp. 737–744, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Huang, M. Van Arsdall, S. Tedjarati et al., “Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice,” Journal of the National Cancer Institute, vol. 94, no. 15, pp. 1134–1142, 2002. View at Publisher · View at Google Scholar · View at Scopus